A5085022307- Multiple Sclerosis Research Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Cell Adhesion Molecules Research
- Barrier Structure and Function Studies
- Alzheimer's disease research and treatments
- Immunotherapy and Immune Responses
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Galectins and Cancer Biology
- Ultrasound and Hyperthermia Applications
- Healthcare Systems and Challenges
- PI3K/AKT/mTOR signaling in cancer
- Tuberous Sclerosis Complex Research
- Probiotics and Fermented Foods
- Gut microbiota and health
- Atherosclerosis and Cardiovascular Diseases
- Systemic Sclerosis and Related Diseases
- Neurological disorders and treatments
- Neurogenesis and neuroplasticity mechanisms
- Cervical and Thoracic Myelopathy
- Pediatric health and respiratory diseases
- Protease and Inhibitor Mechanisms
- Peripheral Neuropathies and Disorders
- Animal Virus Infections Studies
- Proteoglycans and glycosaminoglycans research
University College London Hospitals NHS Foundation Trust
2025
University College London
2025
National Hospital for Neurology and Neurosurgery
2025
William Harvey Research Institute
2021-2024
Queen Mary University of London
2021-2024
University of Oxford
2016-2023
John Radcliffe Hospital
2016-2021
University of Central Missouri
2006
Multiple sclerosis (MS) and Alzheimer's disease are neurodegenerative diseases with age‐related disability accumulation. In MS, inflammation spans decades, whereas AD is characterized by Aβ plaques neurofibrillary tangles (NFT). Few studies explore accumulation of amyloids in MS. We examined deposition NFT density temporal frontal cortices from postmortem MS ( n = 75) control 66) cases. Compared controls, cases showed reduced Aβ, especially those aged <65 years, NFT, notably >65 years....
<ns4:p>Increased clinical and scientific scrutiny is being applied to hepatitis B virus (HBV), with focus on the development of new therapeutic approaches, ultimately aiming for cure. Defining optimum natural CD8+ T cell immune responses that arise in HBV, mediated by HLA class I epitope presentation, may help inform novel immunotherapeutic strategies. Therefore, we have set out develop a comprehensive database these epitopes coined ‘Hepitopes’. This undertaking has its foundations...
Multiple sclerosis (MS) is unsurpassed for its clinical and pathological hetherogeneity, but the biological determinants of this variability are unknown. HLA-DRB1*15, main genetic risk factor MS, influences severity distribution MS pathology. This study set out to unravel molecular heterogeneity pathology in relation HLA-DRB1*15 status. Shotgun proteomics from a discovery cohort spinal cord samples segregated by HLA-DRB*15 status revealed overexpression extracellular matrix (ECM) proteins,...
Selective neuronal vulnerability of hippocampal Cornu Ammonis (CA)-1 neurons is a pathological hallmark Alzheimer's disease (AD) with an unknown underlying mechanism. We interrogated the expression tuberous sclerosis complex-1 (TSC1; hamartin) and mTOR-related proteins in CA1 CA3 subfields.A human post-mortem cohort mild (n = 7) severe 10) AD non-neurological controls 9) was used for quantitative semi-quantitative analyses. also developed vitro TSC1 knockdown model rat neurons,...
Multiple sclerosis (MS) and Alzheimer's disease (AD) are neurodegenerative diseases demonstrating age-related accumulation of disability. Inflammation lasting decades is a paradigmatic feature MS pathology that variably relates to neurodegeneration, while the Amyloid-beta (A-beta) plaques neurofibrillary tangles (NFT) cornerstones AD pathology. However, few studies investigated amyloids in MS. We A-beta deposition NFT density temporal or frontal cortices derived from large post-mortem cohort...
The start date for new junior doctors is referred to as “Black Wednesday,” coined after a 2009 study showed that patients admitted hospital in the first week August had 6-8% higher mortality rate than those last of July.1 As …